Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Standards: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional segments in biopharmaceuticals (haemophilia, growth hormone, and hormone replacement therapy). The company operates in more than 180 countries with over 41,000 employees. In 2014, the company received U.S. approval for Saxenda (liraglutide 3 mg) for weight management, marking its first product for obesity treatment.
Key Financial Metrics (2014)
| Metric | 2014 (DKK Millions) | 2013 (DKK Millions) |
|---|---|---|
| Net Sales | 88,806 | 83,572 |
| Operating Profit | 34,492 | 31,493 |
| Net Profit | 26,481 | 25,184 |
| Earnings Per Share (EPS) | 10.10 | 9.40 |
| Total Assets | 77,062 | 70,337 |
| Net Assets (Equity) | 40,294 | 42,569 |
| Free Cash Flow (Non-IFRS) | 27,396 | 22,358 |
| Net Cash from Operating Activities | 31,692 | 25,942 |
| Capital Expenditure (Net) | 4,000 | 3,200 |
Debt and Liquidity: No long-term loans were outstanding as of December 31, 2014. Current debt was DKK 720 million. Financial resources (cash, bonds, and undrawn credit facilities) totaled DKK 23,373 million. The company maintains a strong liquidity position, financing investments primarily through operating cash flow.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 6.3% to DKK 88.8 billion, driven by volume growth and new product launches, partially offset by price pressures in certain markets.
- Profitability: Operating profit rose 9.5% to DKK 34.5 billion, and net profit increased 5.1% to DKK 26.5 billion.
- Product Portfolio: The diabetes care segment (approx. 79% of sales) continued to grow due to the rollout of Tresiba (insulin degludec) and Victoza. The biopharmaceuticals segment saw stable sales for NovoSeven and growth for Norditropin.
- Patent Expirations: Key compound patents for NovoLog/NovoRapid and NovoLog Mix/NovoMix expired in major markets (US, Europe, Japan) during 2014. However, formulation patents remain in place until 2017, mitigating immediate biosimilar impact.
- Share Repurchases: The company completed a DKK 15 billion share repurchase program in January 2015, having repurchased 59.1 million shares in 2014.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Investments: Expected capital expenditure for 2015 is approximately DKK 5.0 billion, focused on expanding manufacturing capacity for biopharmaceuticals, insulin API, and new research facilities.
- R&D Spend: The company expects R&D expenditure to remain at 13-15% of sales.
- Dividends: A dividend of DKK 5.00 per share was proposed for 2014, representing a payout ratio of 48.7%.
Risks and Contingencies:
- Regulatory and Pricing: Ongoing pressure from payers globally to reduce costs and control prices, particularly in the U.S. market.
- Patent Expiry: While formulation patents protect key products, the expiration of compound patents for insulin products and Prandin/NovoNorm exposes the company to generic competition, particularly in Europe and the U.S.
- Geopolitical: The company conducts business in Iran, Syria, Sudan, and Cuba. Gross revenue from Iran-related transactions in 2014 did not exceed DKK 550 million, and net profit from these activities is estimated to be de minimis.
- Development Risk: Significant uncertainty remains regarding the approval and commercial success of pipeline products, including Semaglutide and faster-acting insulin aspart.
Key Facts for Investor Verification
- Patent Protection Status: Verify the specific expiration dates of formulation patents for NovoLog/NovoRapid and NovoMix in key markets (US, EU, Japan) to assess long-term revenue protection against biosimilars.
- Iran Transactions: Review the specific nature and volume of transactions with Government of Iran (GOI) controlled entities to ensure compliance with U.S. sanctions and executive orders.
- Share Repurchase Impact: Confirm the final number of shares cancelled following the completion of the DKK 15 billion repurchase program and its effect on diluted EPS.
- Free Cash Flow Definition: Note that the company uses a non-IFRS definition of "Free Cash Flow" (operating cash flow less investing cash flow, excluding marketable securities changes) which differs from standard industry definitions.
- Exchange Rate Sensitivity: Assess the impact of the strengthening DKK against the USD (average rate 5.62 in 2014 vs 5.62 in 2013, but period end rate 6.12) on reported USD earnings for U.S. investors.